Tazemetostat
Tazverik (tazemetostat) is a small molecule pharmaceutical. Tazemetostat was first approved as Tazverik on 2020-01-23. The pharmaceutical is active against histone-lysine N-methyltransferase EZH2.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Tazverik
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tazemetostat hydrobromide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TAZVERIK | Epizyme | N-211723 RX | 2020-01-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
tazverik | New Drug Application | 2020-07-31 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
TAZEMETOSTAT HYDROBROMIDE, TAZVERIK, EPIZYME INC | |||
2027-06-18 | ODE-314 | ||
2027-01-23 | ODE-299 | ||
2025-01-23 | NCE | ||
2023-06-18 | I-835, I-836 |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Tazemetostat Hydrobromide, Tazverik, Epizyme Inc | |||
10786511 | 2035-12-19 | DP | |
9889138 | 2035-10-16 | U-2736, U-2852, U-2853 | |
10369155 | 2035-10-16 | U-2736, U-2852, U-2853 | |
9688665 | 2034-08-22 | U-2736 | |
8410088 | 2034-01-23 | DS, DP | |
9394283 | 2033-04-11 | DS, DP | U-2852, U-2853 |
9872862 | 2033-04-11 | U-2738 | |
10245269 | 2033-04-11 | U-2737, U-2851, U-2854 | |
10821113 | 2033-04-11 | DS, DP | |
11491163 | 2033-04-11 | U-3491, U-3492 | |
8765732 | 2032-04-13 | U-2852, U-2853 | |
9090562 | 2032-04-13 | DS, DP | |
9522152 | 2032-04-13 | U-2738 | |
9549931 | 2032-04-13 | U-2736, U-2852, U-2853 | |
9855275 | 2032-04-13 | U-2736 | |
10155002 | 2032-04-13 | U-2736 | |
10420775 | 2032-04-13 | U-2736, U-2852, U-2853 | |
11052093 | 2032-04-13 | DS, DP | U-2736, U-3179 |
8691507 | 2031-09-12 | U-2852 | |
8895245 | 2031-09-12 | U-2852 | |
9175331 | 2031-09-12 | U-2852 | |
9333217 | 2031-09-12 | U-2852 | |
9334527 | 2031-09-12 | U-2852 | |
9949999 | 2031-09-12 | U-2851 |
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sarcoma | D012509 | 3 | 6 | 1 | — | 2 | 10 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Follicular lymphoma | D008224 | C82 | 9 | 7 | — | — | 1 | 11 | |
Neoplasms | D009369 | C80 | 6 | 5 | — | — | — | 9 | |
Non-hodgkin lymphoma | D008228 | C85.9 | 6 | 5 | — | — | — | 9 | |
Rhabdoid tumor | D018335 | 3 | 4 | — | — | — | 6 | ||
Large b-cell lymphoma diffuse | D016403 | C83.3 | 6 | 2 | — | — | — | 6 | |
Synovial sarcoma | D013584 | 3 | 2 | — | — | — | 4 | ||
Mesothelioma | D008654 | C45 | 2 | 2 | — | — | — | 3 | |
Prostatic neoplasms | D011471 | C61 | 3 | 1 | — | — | — | 3 | |
Chordoma | D002817 | EFO_0000334 | 1 | 2 | — | — | 1 | 3 | |
Lymphoma | D008223 | C85.9 | 2 | 1 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell carcinoma | D018288 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TAZEMETOSTAT |
INN | tazemetostat |
Description | Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
|
Classification | Small molecule |
Drug class | enzyme inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1 |
Identifiers
PDB | — |
CAS-ID | 1403254-99-8 |
RxCUI | — |
ChEMBL ID | CHEMBL3414621 |
ChEBI ID | — |
PubChem CID | 66558664 |
DrugBank | DB12887 |
UNII ID | Q40W93WPE1 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tazemetostat - Epizyme
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,351 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
1,003 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more